secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-10-13T12:41:52+00:00
Accession:  0001437749-26-032505
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Phio completes first commercial-scale cGMP batch of PH-762; Phase 2b trial set for Q1 2027
--------------------------------------------------------------------------------

- PH-762 drug substance (API) batch released meeting established specs, confirmed by Certificate of Analysis and Certificate of Compliance.
- Manufactured under cGMP, the approved Master Batch Record and ICH Q7 guidelines, per the October 13, 2026 press release.
- Validated material moves to final drug product completion for Phio's planned Phase 2b clinical study, expected to begin Q1 2027.
- CEO Robert Bitterman said the milestone culminates a complex 16-month cross-functional effort and mitigates key development and manufacturing risks.
- Phio is a clinical-stage biotech developing cancer therapeutics on its INTASYL siRNA gene-silencing platform; PH-762 is the lead program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926032505/0001437749-26-032505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926032505/phio20261008_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer